Physician profile
Steven E Fern
NPI 1417982760
$17,921.02
in general payments reported to CMS, 2019-2025
47 companies · $522 in 2025
The $522 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,762 · 2020: $7,298 · 2021: $2,804 · 2022: $1,596 · 2023: $1,486 · 2024: $1,454 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,461.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $5,364.31 | 2019-2021 | |
| Abbvie INC. | $3,803.76 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,791.56 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,128.72 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $696.36 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $561.29 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $505.25 | 2019-2024 | Verquvo |
| Ucb, INC. | $467.66 | 2019-2021 | |
| Romark Laboratories, Lc | $337.71 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $335.69 | 2024 | Voquezna |
| Pfizer INC. | $316.54 | 2019-2025 | |
| Celgene Corporation | $293.70 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $276.30 | 2019-2021 | |
| Gilead Sciences, INC. | $208.43 | 2024-2025 | Livdelzi |
| Medtronic, INC. | $185.93 | 2021-2022 |
Show all 43 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Fern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.